Abiomed Announces Record Revenue of $261 Million, up 13% Year Over Year

Rhea-AI Summary

ABIOMED, Inc. (NASDAQ: ABMD) reported robust Q3 2022 results with revenues of $261 million, a 13% increase year-over-year. Impella heart pump revenues reached $249 million, up 13%, driven by a 10% increase in U.S. patient utilization. The company enhanced its fiscal year 2022 revenue guidance to $1,025-$1,030 million, projecting growth of 21%-22%. Non-GAAP net income was $52 million, equating to $1.13 per diluted share. ABIOMED also received multiple regulatory approvals for its Impella products and presented significant clinical data at TCT 2021.

Positive

• Q3 2022 revenue of $261 million, a 13% increase YoY.
• Impella product revenue increased to $249 million, a 13% rise.
• U.S. Impella product revenue grew by 12%, aided by 10% patient utilization increase.
• Increased fiscal year 2022 revenue guidance to $1,025-$1,030 million, reflecting 21%-22% growth.
• Non-GAAP net income of $52 million, or $1.13 per diluted share.

Negative

• Gross margin decreased from 82.3% to 81.8% YoY.
• Non-GAAP operating margin dropped to 24.9% from 30.8% YoY.

Increasing Low End of Guidance: $1,025 Million - $1,030 Million, up 21% - 22%

DANVERS, Mass.--(BUSINESS WIRE)-- ABIOMED, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced financial results for the quarter ended December 31, 2021.

Q3 financial summary and operational highlights:

• Revenue for the quarter totaled $261 million, an increase of 13% compared to $232 million during the same period of the prior fiscal year. In constant currency,* revenue increased 14% compared to the same period of the prior fiscal year.
• Worldwide Impella® heart pump product revenue for the quarter totaled $249 million, an increase of 13% compared to $221 million during the same period of the prior fiscal year. In constant currency,* revenue increased 14% compared to the same period of the prior fiscal year.
• U.S. Impella product revenue for the quarter totaled $201 million, an increase of 12% compared to $180 million during the same period of the prior fiscal year due to a 10% increase in patient utilization.
• Outside the U.S., Impella product revenue for the quarter totaled $48 million, an increase of 16% compared to $41 million during the same period of the prior fiscal year. In constant currency,* outside the U.S., Impella product revenue increased 22% compared to the same period of the prior fiscal year.
  • Europe product revenue for the quarter totaled $31 million, an increase of 13% compared to $28 million during the same period of the prior fiscal year. In constant currency,* Europe product revenue increased 18% compared to the same period of the prior fiscal year due to a 13% increase in patient utilization.
  • Japan product revenue for the quarter totaled $14 million, an increase of 16% compared to $12 million during the same period of the prior fiscal year. In constant currency,* Japan product revenue increased 27% compared to the same period of the prior fiscal year due to a 35% increase in patient utilization.
• Gross margin for the quarter was 81.8% compared to 82.3% during the same period of the prior fiscal year.
• Non-GAAP income from operations* was $65 million or 24.9% non-GAAP operating margin* for the quarter, compared to $71 million non-GAAP income from operations* or 30.8% non-GAAP operating margin* during the same period of the prior fiscal year, primarily due to increased investment in innovation, clinical evidence and building a premier distribution team. GAAP income from operations was $65 million or 24.7% GAAP operating margin for the quarter, compared to $71 million GAAP income from operations or 30.8% GAAP operating margin during the same period of the prior fiscal year.
• Non-GAAP net income* was $52 million, or $1.13 per diluted share, compared to non-GAAP net income* of $54 million, or $1.17 per diluted share during the same period of the prior fiscal year. GAAP net income was $46 million, or $1.00 per diluted share compared to $62 million GAAP net income or $1.35 per diluted share during the same period of the prior fiscal year.
• The company generated operating cash flows of $90 million during the quarter. As of December 31, 2021, the company had $932 million of cash and cash equivalents and marketable securities and no debt.
• On November 3, the company announced the 2021 guidelines of the European Society of Cardiology (ESC) for treatment of acute heart failure patients, including patients in cardiogenic shock, raised the recommendation level for short-term mechanical circulatory support systems, such as Impella heart pumps, from Class IIb ("may be considered") to Class IIa ("should be considered"). This is the first update of the ESC guidelines in five years and reflects the growing body of robust clinical evidence supporting the use of Impella for cardiogenic shock patients.
• On November 4, physician experts and principal investigators of the PROTECT IV RCT, the RECOVER IV RCT and the STEMI Door-to-Unloading RCT presented robust, high-quality data and clinical studies of Impella heart pumps at Transcatheter Cardiovascular Therapeutics (TCT) 2021, the annual scientific symposium of the Cardiovascular Research Foundation. Presentations included the final results of the PROTECT III and Restore EF prospective studies, an update on the on-going RCTs and a review of the clinical experience with the new 9 French Impella ECP heart pump. The presentations are available for on-demand viewing at this link.
• On January 10, the company announced that regulators in three countries granted approvals to Impella surgical products. In Japan, Impella 5.5 with SmartAssist has received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). In the United States, the Food and Drug Administration (FDA) granted an Early Feasibility Study (EFS) Investigational Device Exemption (IDE) to Impella BTR (Bridge-to-Recovery). In Hong Kong, Impella 5.5 with SmartAssist has received approval from the Medical Device Division (MDD).
• On January 12, Chairman, President and Chief Executive Officer, Michael R. Minogue, presented at the 40^th Annual J.P. Morgan Healthcare Conference. The presentation provides a brief overview of the company and a deep dive on Abiomed’s breakthrough innovation, robust clinical evidence, and premier clinical field team.
• On January 12, the company announced the successful results of the first-in-human EFS of the preCARDIA system. The preCARDIA system is designed to improve decongestion in acutely decompensated heart failure (ADHF) patients by intermittently occluding the superior vena cava. The study met the safety and feasibility endpoints, and the results of the study were published in the journal Circulation: Heart Failure.

“Despite a slower start in October due to the COVID resurgence and hospital labor shortages, our Abiomed 2.0 playbook allowed us to adapt and execute, grow sequentially, and support the most patients ever in a quarter. These record results would not have been possible without the dedication of our customers and employees supporting critically ill patients 24 x 7 on-site, online and in the cloud with Impella Connect,” said Michael R. Minogue, Abiomed’s Chairman, President and Chief Executive Officer. “Our focus on extending our lead in innovation, advancing clinical evidence, and building a premier commercial team enables the pursuit of becoming the global standard of care for hemodynamic support.”

FISCAL YEAR 2022 OUTLOOK

The company is increasing the lower end of its fiscal year 2022 revenue guidance to a range of $1,025 million to $1,030 million with growth of 21% - 22% versus prior year. This compares to the previous quarter guidance of $1,010 million to $1,030 million, an increase of 19% - 22%. The company expects its fiscal year 2022 non-GAAP operating margin* to be in the range of 24% - 25%.

*ABOUT NON-GAAP FINANCIAL MEASURES

To supplement its condensed consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the company uses non-GAAP financial measures as described below. The company uses these non-GAAP financial measures for financial and operational decision-making and to evaluate period-to-period comparisons. The company believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance and liquidity. The company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance and when planning, forecasting, and analyzing future periods. The company believes these non-GAAP financial measures are useful to investors because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by institutional investors and the analyst community to help them analyze the performance of the company’s business.

The company uses the following non-GAAP financial measures:

Non-GAAP operating income: The company defines non-GAAP operating income as operating income, excluding charges for the acquired in-process research and development related to the preCARDIA acquisition.

Non-GAAP operating margin: The company defines non-GAAP operating margin as operating margin, excluding charges for the acquired in-process research and development related to the preCARDIA acquisition.

Non-GAAP net income and net income per diluted share: The company defines non-GAAP net income and net income per diluted share as net income and net income per diluted share, excluding charges for the acquired in-process research and development related to the preCARDIA acquisition, the gain recognized on its previously owned minority interest in preCARDIA, unrealized losses/ gains on investment in Shockwave Medical and excess tax benefits associated with stock-based compensation. The company defines non-GAAP EPS as non-GAAP net income divided by non-GAAP diluted shares, which are calculated as GAAP weighted average outstanding shares plus dilutive potential shares outstanding during the period.

Constant currency: The company defines constant currency revenue growth as the change in revenue between current and prior year periods using a constant currency, the exchange rate in effect during the applicable prior year period. The company presents constant currency revenue growth because management believes it provides meaningful information regarding the company’s revenue results on a consistent and comparable basis.

Refer to the “Reconciliation of GAAP to Non-GAAP Financial Measures” section of this press release.

The company reports non-GAAP financial measures in addition to, and not as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. These non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles, differ from GAAP measures with the same names, and may differ from non-GAAP financial measures with the same or similar names that are used by other companies. The company believes it is useful to exclude certain items because such amounts in any specific period may not directly correlate to the underlying performance of its business operations or can vary significantly between periods. The company believes that non-GAAP financial measures should only be used to evaluate our results of operations in conjunction with the corresponding GAAP financial measures. The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand its business.

EARNINGS CONFERENCE CALL DETAILS

The company will host a conference call to discuss the quarterly results at 8:00 a.m. ET on Thursday, February 3, 2022. The conference call will be hosted by Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Vice President and Chief Financial Officer.

To listen to the call live, please tune into the webcast via https://investors.abiomed.com/events-presentations or dial (844) 200-6205; the international number is (929) 526-1599 access code 898485. A replay of this conference call will be available until Thursday, February 10, 2022. The replay phone number is (866) 813-9403; the international number is +44 204 525 0658. The replay access code is 017050.

ABOUT ABIOMED

Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com. Abiomed, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, Impella 5.5, Impella Connect, and SmartAssist are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries. Impella ECP, Impella XR Sheath, Impella BTR, CVAD STUDY, STEMI DTU, Automated Impella Controller and Abiomed Breethe OXY-1 System and preCARDIA are pending trademarks of Abiomed, Inc.

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including, without limitation, statements regarding development of Abiomed's existing and new products, the company's progress toward commercial growth, future opportunities and expected regulatory approvals and statements in the paragraph under “Fiscal Year 2022 Outlook” section regarding certain business metrics on either or both a GAAP or non-GAAP basis. All statements, other than statements of historical facts, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “should,” “likely,” “will” and other words and terms of similar meaning. The company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including, without limitation: the scope, scale and duration of the impact of the COVID-19 pandemic, the company’s dependence on Impella® products for all of its revenues; the company’s ability to successfully compete against its existing or potential competitors; the acceptance of the company’s products by cardiac surgeons and interventional cardiologists; long sales and training cycles associated with expansion into new hospital cardiac centers; reduced market acceptance of the company’s products due to lengthy clinician training process; the company’s ability to effectively manage its growth; the company’s ability to successfully commercialize its products; the company’s ability to obtain regulatory approvals and market and sell its products in certain jurisdictions; enforcement actions and product liability suits relating to off-label uses of the company’s products; unsuccessful clinical trials or procedures relating to products under development; the company’s ability to maintain compliance with regulatory requirements; the failure of third-party payers to provide reimbursement of the company’s products; the company’s ability to increase manufacturing capacity to support continued demand for its products; the company or its vendors’ failure to achieve and maintain high manufacturing standards; the failure of the company’s suppliers to provide the components the company requires; the company’s ability to expand its direct sales activities into international markets; the outcome of ongoing securities class action litigation relating to our public disclosures, the company’s ability to integrate acquired companies into its operations and other risks and challenges detailed in the company's filings with the Securities and Exchange Commission (the “SEC”), including the most recently filed Annual Report on Form 10-K and the filings subsequently filed with or furnished to the SEC. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. Unless otherwise required by law, the company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Abiomed, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(Unaudited)
(in thousands)
		December 31, 2021				March 31, 2021
ASSETS
Current assets:
Cash and cash equivalents		$	144,255			$	232,710
Short-term marketable securities			524,966				350,985
Accounts receivable, net			88,952				97,179
Inventories, net			90,199				81,059
Prepaid expenses and other current assets			36,634				26,032
Total current assets			885,006				787,965
Long-term marketable securities			262,635				264,085
Property and equipment, net			196,880				197,129
Goodwill			77,449				78,568
Other intangibles, net			40,278				42,150
Deferred tax assets			3,680				11,380
Other assets			126,949				113,082
Total assets		$	1,592,877			$	1,494,359
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable		$	32,066			$	34,842
Accrued expenses			66,668				66,046
Deferred revenue			24,867				24,322
Other current liabilities			3,195				3,759
Total current liabilities			126,796				128,969
Other long-term liabilities			10,805				10,162
Contingent consideration			21,539				24,706
Deferred tax liabilities			799				847
Total liabilities			159,939				164,684
Stockholders' equity:
Class B Preferred Stock, $.01 par value			—				—
1,000 shares authorized; issued and outstanding - none
Common stock, $.01 par value			455				453
100,000 shares authorized; 48,229 and 47,929 shares issued as of December 31, 2021 and March 31, 2021, respectively
45,516 and 45,271 shares outstanding as of December 31, 2021 and March 31, 2021, respectively
Additional paid in capital			853,210				800,690
Retained earnings			904,187				828,007
Treasury stock at cost - 2,713 and 2,658 shares as of December 31, 2021 and March 31, 2021, respectively			(304,425	)			(288,030	)
Accumulated other comprehensive loss			(20,489	)			(11,445	)
Total stockholders' equity			1,432,938				1,329,675
Total liabilities and stockholders' equity		$	1,592,877			$	1,494,359

Abiomed, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(Unaudited)
(in thousands, except per share data)
		For the Three Months Ended December 31,							For the Nine Months Ended December 31,
			2021				2020			2021			2020
Revenue		$	261,176			$	231,663		$	761,903		$	606,277
Costs and expenses:
Cost of revenue			47,627				41,110			136,701			115,829
Research and development			40,869				33,004			119,618			89,886
Selling, general and administrative			107,618				86,198			313,881			233,809
Acquired in-process research and development			496				—			115,986			—
			196,610				160,312			686,186			439,524
Operating income			64,566				71,351			75,717			166,753
Other (loss) income:
Investment income, net			891				1,449			2,918			5,668
Other (loss) income, net			(7,580	)			7,935			37,163			42,305
			(6,689	)			9,384			40,081			47,973
Income before income taxes			57,877				80,735			115,798			214,726
Income tax provision			12,125				18,867			39,618			46,057
Net income		$	45,752			$	61,868		$	76,180		$	168,669
Net income per share - basic		$	1.01			$	1.37		$	1.68		$	3.74
Weighted average shares outstanding - basic			45,508				45,201			45,419			45,105
Net income per share - diluted		$	1.00			$	1.35		$	1.66		$	3.69
Weighted average shares outstanding - diluted			45,921				45,706			45,851			45,653

Abiomed, Inc. and Subsidiaries
Reconciliation of GAAP to Non-GAAP Financial Measures
(Unaudited)
(in thousands, except per share data)
	For the Three Months Ended December 31,								For the Nine Months Ended December 31,
		2021				2020				2021				2020
GAAP operating income	$	64,566			$	71,351			$	75,717			$	166,753
Acquired in-process research and development (1)		496				—				115,986				—
Non-GAAP operating income	$	65,062			$	71,351			$	191,703			$	166,753
GAAP operating margin		24.7	%			30.8	%			9.9	%			27.5	%
Non-GAAP operating margin		24.9	%			30.8	%			25.2	%			27.5	%
GAAP net income		45,752			$	61,868			$	76,180			$	168,669
Acquired in-process research and development (1)		496				—				115,986				—
Gain on previously held interest in preCARDIA (2)		—				—				(20,980	)			—
Loss (gain) on investment in Shockwave Medical (3)		6,164				(6,237	)			(10,748	)			(32,338	)
Excess tax benefits on stock-based compensation (4)		(338	)			(1,909	)			(10,139	)			(10,363	)
Non-GAAP net income	$	52,074			$	53,722			$	150,299			$	125,968
GAAP diluted net income per share	$	1.00			$	1.35			$	1.66			$	3.69
Acquired in-process research and development (1)		0.01				—				2.53				—
Gain on previously held interest in preCARDIA (2)		—				—				(0.46	)			—
Loss (gain) on investment in Shockwave Medical (3)		0.13				(0.14	)			(0.23	)			(0.71	)
Excess tax benefits on stock-based compensation (4)		(0.01	)			(0.04	)			(0.22	)			(0.23	)
Non-GAAP diluted net income per share	$	1.13			$	1.17			$	3.28			$	2.75
GAAP diluted weighted-average shares outstanding		45,921				45,706				45,851				45,653
Non-GAAP diluted weighted-average shares outstanding		45,921				45,706				45,851				45,653

Notes:

(1) In May 2021, the company acquired the remaining interest in preCARDIA for $82.8 million. The company determined that substantially all of the fair value of the acquisition related to the acquired in-process research and development asset, which resulted in accounting for the transaction as an asset acquisition. The fair value of the acquired in-process research and development asset of $115.5 million is primarily comprised of the net consideration paid for the acquired remaining interest of $82.8 million and our previously owned minority interest in preCARDIA of $32.4 million. During the three months ended December 31, 2021, the Company made a holdback payment of $0.5 million to former shareholders of preCARDIA. Since the acquired technology platform is pre-commercial and has not reached technical feasibility as defined by the accounting rules, the cost of the in-process research and development asset was expensed, resulting in a charge of $116 million for the nine months ended December 31, 2021.

(2) The company recognized a gain of $21 million related to its previously owned minority interest in preCARDIA as described in note (1) above, within the condensed consolidated statement of operations for the nine months ended December 31, 2021.

(3) Amount represents the unrealized loss (gain) on investment in Shockwave Medical in each respective period presented. The company recognized an unrealized loss on investment in Shockwave Medical of $8.2 million ($6.2 million, net of tax benefit) and an unrealized gain of $8.3 million ($6.2 million, net of tax benefit) within other (loss) income, net for the three months ended December 31, 2021 and 2020, respectively. The company recognized an unrealized gain on investment in Shockwave Medical of $14.3 million ($10.7 million, net of tax benefit) and $43 million ($32.3 million, net of tax benefit) within other (loss) income, net for the nine months ended December 31, 2021 and 2020, respectively.

(4) Amount represents the impact of excess tax benefits associated with stock-based compensation in each respective period presented. The company recognized excess tax benefits associated with stock-based compensation of $0.3 million and $1.9 million as an income tax benefit for the three months ended December 31, 2021 and 2020, respectively. The company recognized excess tax benefits associated with stock-based compensation of $10.1 million and $10.4 million as an income tax benefit for the nine months ended December 31, 2021 and 2020, respectively.

Abiomed, Inc. and Subsidiaries
Reconciliation of GAAP to Non-GAAP Constant Currency
(Unaudited)
(in thousands)
Total revenue by region:
		For the Three Months Ended December 31,
			2021			2020		% Change			Currency Impact				Constant Currency*
United States		$	211,957		$	189,116		12	%		—		%		12	%
Europe			32,379			28,630		13	%		5		%		18	%
Japan			14,021			12,012		17	%		10		%		27	%
Rest of world			2,819			1,905		48	%		—		%		48	%
Outside the U.S.			49,219			42,547		16	%		6		%		22	%
Total revenue		$	261,176		$	231,663		13	%		1		%		14	%
		For the Nine Months Ended December 31,
			2021			2020		% Change			Currency Impact				Constant Currency*
United States		$	619,585		$	495,988		25	%		—		%		25	%
Europe			97,143			73,638		32	%		(2	)	%		30	%
Japan			37,572			31,308		20	%		6		%		26	%
Rest of world			7,603			5,343		42	%		—		%		42	%
Outside the U.S.			142,318			110,289		29	%		1		%		30	%
Total revenue		$	761,903		$	606,277		26	%		—		%		26	%
Product revenue by region:
		For the Three Months Ended December 31,
			2021			2020		% Change			Currency Impact				Constant Currency*
United States		$	201,404		$	179,612		12	%		—		%		12	%
Europe			31,266			27,666		13	%		5		%		18	%
Japan			13,575			11,663		16	%		11		%		27	%
Rest of world			2,820			1,906		48	%		—		%		48	%
Outside the U.S.			47,661			41,235		16	%		6		%		22	%
Total product revenue		$	249,065		$	220,847		13	%		1		%		14	%
		For the Three Months Ended December 31,
			2021			2020		% Change			Currency Impact				Constant Currency*
United States		$	588,624		$	469,038		25	%		—		%		25	%
Europe			93,823			71,083		32	%		(2	)	%		30	%
Japan			36,273			30,477		19	%		6		%		25	%
Rest of world			7,604			5,343		42	%		—		%		42	%
Outside the U.S.			137,700			106,902		29	%		—		%		29	%
Total product revenue		$	726,324		$	575,940		26	%		—		%		26	%

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20220203005280/en/

For further information:

Todd Trapp

Vice President and Chief Financial Officer

978-646-1680

ttrapp@abiomed.com

Tom Langford

Director, Corporate Communications & PR

978-882-8408

tlangford@abiomed.com

Source: Abiomed, Inc.

FAQ

What were ABIOMED's Q3 2022 financial results?

ABIOMED reported Q3 2022 revenues of $261 million, a 13% increase year-over-year, with Impella product revenue at $249 million.

What is ABIOMED's updated revenue guidance for fiscal year 2022?

ABIOMED increased its revenue guidance for fiscal year 2022 to $1,025-$1,030 million, representing growth of 21%-22%.

What were the non-GAAP earnings per share for ABIOMED in Q3 2022?

ABIOMED's non-GAAP net income was $52 million or $1.13 per diluted share for Q3 2022.

Did ABIOMED receive any regulatory approvals recently?

Yes, ABIOMED received approvals for Impella products in Japan, the U.S., and Hong Kong.

What was the gross margin for ABIOMED in Q3 2022?

The gross margin for Q3 2022 was 81.8%, a decline from 82.3% in the prior year.